NEW YORK (GenomeWeb) — German molecular diagnostics firm Curetis said today that it has closed a €14.5 million ($18 million) extension of its Series B financing round originally led by HBM partners in April 2013.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.
Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.
In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.
Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.